Primary Sclerosing Cholangitis - Pipeline Review, H1 2020

January 2020 | 128 pages | ID: PC5C048AE28EN
Global Markets Direct

Abstracts

Primary Sclerosing Cholangitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2020, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 7, 3, 1, 10 and 3 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Primary Sclerosing Cholangitis - Overview
Primary Sclerosing Cholangitis - Therapeutics Development
Primary Sclerosing Cholangitis - Therapeutics Assessment
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
Primary Sclerosing Cholangitis - Drug Profiles
Primary Sclerosing Cholangitis - Dormant Projects
Primary Sclerosing Cholangitis - Discontinued Products
Primary Sclerosing Cholangitis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by BiomX Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by ChemomAb Ltd, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Emergent Biotechnologies LLC, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Engitix Ltd, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Immunic Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Mirum Pharmaceuticals Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Morphic Holding Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Nyrada Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Orbsen Therapeutics Ltd, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Pliant Therapeutics Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Qing Bile Therapeutics Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H1 2020
Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Primary Sclerosing Cholangitis - Dormant Projects, H1 2020
Primary Sclerosing Cholangitis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Albireo Pharma Inc
Allergan Plc
BiomX Inc
ChemomAb Ltd
Dr. Falk Pharma GmbH
Emergent Biotechnologies LLC
Engitix Ltd
Gilead Sciences Inc
Immunic Inc
Intercept Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
Morphic Holding Inc
NGM Biopharmaceuticals Inc
Nyrada Inc
Orbsen Therapeutics Ltd
Pliant Therapeutics Inc
Qing Bile Therapeutics Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Sirnaomics Inc
Takeda Pharmaceutical Co Ltd